Lucerastat

Lucerastat, the galactose form of Miglustat, is an orally-available inhibitor of glucosylceramide synthase (GCS) . Lucerastat has the potential for Fabry disease study[1][2].

Product Specifications

CAS Number

[141206-42-0]

Product Name Alternative

NB-DGJ; N- (n-Butyl) deoxygalactonojirimycin

UNSPSC

12352005

Hazard Statement

H315, H319

Target

Glucosylceramide Synthase (GCS)

Type

Reference compound

Related Pathways

Neuronal Signaling

Applications

Metabolism-protein/nucleotide metabolism

Field of Research

Metabolic Disease

Assay Protocol

https://www.medchemexpress.com/lucerastat.html

Purity

98.0

Solubility

DMSO : 22 mg/mL (ultrasonic; warming; heat to 80°C) |H2O : 24 mg/mL (ultrasonic; warming; heat to 80°C)

Smiles

O[C@H]1[C@@H](CO)N(CCCC)C[C@H](O)[C@H]1O

Molecular Formula

C10H21NO4

Molecular Weight

219.28

Precautions

H315, H319

References & Citations

[1]Sanne J van der Veen, et al. Developments in the Treatment of Fabry Disease. J Inherit Metab Dis. 2020 Feb 21.|[2]R.W.D. Welford, et al. Lucerastat, an Iminosugar for Substrate Reduction Therapy in Fabry Disease: Preclinical Evidence.